FDA Inspection 1098544 — Anapharm Europe
The FDA completed an inspection of Anapharm Europe on June 7, 2019 in Barcelona. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- June 7, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Barcelona (Spain)
Additional Details
Bioanalytical BA/BE